Murphy Pohlad Asset Management LLC Reduces Stock Position in OraSure Technologies, Inc. $OSUR

Murphy Pohlad Asset Management LLC reduced its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 9.1% in the second quarter, HoldingsChannel.com reports. The firm owned 79,567 shares of the medical instruments supplier’s stock after selling 8,000 shares during the period. Murphy Pohlad Asset Management LLC’s holdings in OraSure Technologies were worth $239,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Jacobs Levy Equity Management Inc. boosted its holdings in shares of OraSure Technologies by 39.3% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,290,554 shares of the medical instruments supplier’s stock worth $4,349,000 after purchasing an additional 363,946 shares during the period. Strs Ohio bought a new position in OraSure Technologies in the first quarter worth about $481,000. Gagnon Securities LLC raised its stake in OraSure Technologies by 49.4% in the second quarter. Gagnon Securities LLC now owns 1,604,142 shares of the medical instruments supplier’s stock worth $4,812,000 after buying an additional 530,371 shares in the last quarter. Gagnon Advisors LLC raised its stake in OraSure Technologies by 51.4% in the second quarter. Gagnon Advisors LLC now owns 1,207,440 shares of the medical instruments supplier’s stock worth $3,622,000 after buying an additional 410,163 shares in the last quarter. Finally, Bridgeway Capital Management LLC raised its stake in OraSure Technologies by 32.9% in the first quarter. Bridgeway Capital Management LLC now owns 1,635,275 shares of the medical instruments supplier’s stock worth $5,511,000 after buying an additional 405,169 shares in the last quarter. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of OraSure Technologies in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $3.00.

OraSure Technologies Stock Performance

Shares of NASDAQ OSUR opened at $2.70 on Friday. OraSure Technologies, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $4.60. The company has a 50 day simple moving average of $3.15 and a two-hundred day simple moving average of $3.01. The company has a market capitalization of $197.48 million, a price-to-earnings ratio of -4.03 and a beta of 0.46.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.